Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

A recently published study revealed significant sex-based disparities in emergency department empiric antibiotic treatment ...

Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.

Long-acting lipoglycopeptides are as effective as standard-of-care antibiotics in treating serious bacterial infections in ...

Inappropriate polypharmacy—the excessive or unnecessary use of multiple medications—is a major driver of emergency hospital ...

Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with ...

The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.

Middle ear infection in children is much more common than in adults, in part because of how this part of the ear is designed.

Khatri is funded by a grant from the National Institute on Drug Abuse. Data for this manuscript came from the Institute for ...

Stockholm, Sweden Monday, June 30, 2025, 10:00 Hrs [IST] ...

Dental care delays are common, but they come with risks. Learn what causes them and how we can change the pattern.